November 2025
Genexgen is super excited to welcome Dr. Snow Ge to its advisory board
Dr. Snow Ge has over 20 years of biopharmaceutical industry experience in drug discovery and development with extensive knowledge of the overall drug development process and FDA/EMA regulations and guidance. She has contributed to successful IND submissions and NDA approvals in different therapeutic areas and experienced interactions with global regulatory agencies. Dr. Ge is Sr. Vice President of Clinical Pharmacology at BridgeBio Pharma and a member of Life Science Angel. She is also an advisor to UC Berkeley SkyDeck, Bakar Labs, UCSF Catalyst program, and Stanford School of Medicine Spark Program. Prior to BridgeBio, Dr. Ge worked at Nektar Therapeutics, GSK, and Schering AG, and did her postdoctoral research at UC, Berkeley. Dr. Ge has a Ph.D. in Chemistry from the University of British Columbia and B.S. in Chemistry from Peking University. Dr. Ge is also Regulatory Affairs Certified (RAC) by Regulatory Affairs Certification Board.
November 2025
Genexgen is excited to join Berkeley SkyDeck accelerator program
Genexgen has further deepened its ties with the University of California, Berkeley and its dynamic innovation community, and has secured equity financing from the Berkeley SkyDeck Fund.
September 2025
Genexgen is honoured to add Dr. Carl Allen and Dr. Ken McClain to its Advisory Board
Dr. Carl Allen is the Milton and Allene Nirken Chair in Pediatric Oncology at Texas Children's Hospital and co-director of the Texas Children’s Cancer Center Histiocytosis and Lymphoma Programs, where he leads a team of over 30 clinicians and scientists dedicated to improving the outcomes of children and adults with histiocytic disorders, lymphoma and lymphoproliferative disorders.
Dr. Kenneth McClain is Director of the Histiocytosis Program at Texas Children’s Cancer and Hematology Center and a member of the leukemia and lymphoma programs. Dr. McClain and Dr. Carl Allen see 150 newly-diagnosed patients with a variety of histiocytic diseases each year and follow more than 1,000 active patients, including patients from five continents.
July 2025
Genexgen Submits Orphan Drug Designation Application to FDA for HLH Therapy
Genexgen has officially submitted its Orphan Drug Designation (ODD) application to the U.S. Food and Drug Administration for the treatment of Hemophagocytic Lymphohistiocytosis (HLH), a rare and severe pediatric hyperinflammatory genetic disorder.
This marks a major scientific and operational milestone in Genexgen’s mission to unlock a healthier, longer life through precision control of immunity. By targeting HLH and leveraging the accelerated regulatory pathway for rare diseases, Genexgen aims to rapidly evaluate the safety and efficacy of its epigenetic modulation platform in humans. This first-in-human validation sets the stage for addressing one of the key hallmarks of aging-related diseases: chronic systemic inflammation, also known as inflammaging.
January 2025
Samira Kiani received the Presidential Early Career Award for Scientists and Engineers, the U.S. government’s highest honor to outstanding scientists and engineers early in their careers.
September 2024
Genexgen is awarded NSF STTR Phase 1, to advance its technology to control unwanted immune response in cell and gene therapies, autoimmunity, and transplantation.
December 2021
CF Foundation Awards More Than $1.8M to Three Companies for Genetic Therapies Research
The Foundation funded its first program directly aimed at reducing or eliminating the potential immune response from a viral delivery method. GenexGen Inc. was awarded nearly $595,000 to develop a drug that is designed to dampen the body’s immune system response